Medication/Zoladex

From Transsexual Support

Goserelin/Zoladex is an injectable gonadotropin releasing hormone super-agonist (GnRH agonist). It stops the production of sex hormones (testosterone and oestrogen).

Goserelin is marketed by AstraZeneca with the brand name Zoladex.[1] It was first launched in 1987 and is currently the second-largest selling GnRH analogue in the world. It is currently available in more than one hundred markets.

Zoladex 3.6 mg subcutaneous monthly biodegradable implant was first approved by the FDA on November 3, 1989[2] for treatment of prostate cancer, a 10.8 mg subcutaneous 3-month biodegradable implant and other indications were subsequently approved.